<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2908245847
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Uridisitol
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TOLTERODINE TARTRATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        52.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hetero Labs Limited Unit &#x2013; V" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hetero Labs Limited Unit – V
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2950]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G04BD07
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance in Uridisitol is Tolterodine. Tolterodine belongs to a class of medicinal products called antimuscarinics.</p><p>Uridisitol is used for the treatment of the symptoms of overactive bladder syndrome. if you have overact ive bladder syndrome, you may find that:</p><p>&bull;&nbsp; you are unable to control urination,</p><p>&bull;&nbsp; you need to rush to the toilet with no advance warning and/or go to the toilet frequently.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Uridisitol if you:</strong></p><p>&bull;&nbsp; are allergic (hypersensitive) to Uridisitol or any of the other ingredients in Uridisitol</p><p>(listed in.section 6)</p><p>&bull;&nbsp; are unable to pass urine from the bladder (urinary retention)</p><p>&nbsp;</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp; have an uncontro<strong>l </strong>ed narrow-angle glaucoma (high pressure in&nbsp; the&nbsp; eyes&nbsp; with&nbsp; loss&nbsp; of eyesight&nbsp; that&nbsp; is&nbsp; not being adequately treated)</p><p>&bull;&nbsp; suffer from myasthenia gravis (excessive weakness of the muscles)</p><p>&bull;&nbsp; suffer from severe ulcerative colitis (ulceration and inflammation of the colon)</p><p>&bull;&nbsp; suffer from a toxic megacolon (acute dilatation of the colon).</p><p>Warnings and precautions</p><p>If you have difficulties in passing urine and/or a poor stream of urine</p><p>&bull;&nbsp; If you have a gastro-intestinal disease that affects the passage and/or digestion of food</p><p>&bull;&nbsp; If you suffer from kidney problems (renal insufficiency)</p><p>&bull;&nbsp; If you have a liver condition</p><p>&bull;&nbsp; If you suffer from neuronal disorders that affect your blood pressure, bowel or sexual function (any neuropathy of the autonomic nervous system)</p><p>&bull;&nbsp; If you have a hiatal hernia (herniation of an abdominal organ)</p><p>&bull; If you ever experience decreased bowel movements or suffer from severe constipation (decreased gastro-intestinal motility)</p><p>&bull;&nbsp; If you have a heart condition such as:</p><p>▪&nbsp; an abnormal heart tracing (ECG);</p><p>▪&nbsp; a slow heart rate (bradycardia);</p><p>▪&nbsp; relevant pre-existing cardiac diseases such as:</p><p>- cardiomyopathy (weak heart muscle)</p><p><strong>- </strong>myocardial ischaemia (reduced blood flow to the heart)</p><p>-&nbsp; arrhythmia (irregular heartbeat)</p><p>-&nbsp; and heart failure</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; If you have abnorma<strong>l </strong>y low levels of potassium (hypokalaemia),&nbsp; calcium&nbsp; (hypocalcaemia)&nbsp; or magnesium (hypomagnesaemia) in your blood</p><p>Talk&nbsp; to&nbsp; your doctor or pharmacist before&nbsp; starting your treatment with Uridisitol&nbsp; if you&nbsp; think&nbsp; any&nbsp; of these might apply to you.</p><p>Other medicines and Uridisitol</p><p>Tolterodine, the active substance&nbsp; of Uridisitol, may interact&nbsp; with other medicinal&nbsp; products. It is not recommended to use tolterodine in combination with:</p><p>&nbsp;</p><p>&nbsp;</p><p>&bull;&nbsp; some antibiotics (containing e.g. erythromycin, clarithromycin)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; medicinal products used for the treatment of fungal infections (containing e.g. ketoconazole, itraconazole)</p><p>&bull;&nbsp; medicinal products used for the treatment of HIV.</p><p>Uridisitol should be used with caution when taken in combination with:</p><p>&bull;&nbsp; medicines that affect the passage of food (containing e.g. metoclopramide and cisapride)</p><p>&bull;&nbsp;&nbsp;&nbsp; medicines for the treatment of irregular heartbeat (containing e.g. amiodarone, sotalol, quinidine, procainamide)</p><p>&bull;&nbsp;&nbsp;&nbsp; other medicines with&nbsp; a&nbsp; similar&nbsp; mode of action&nbsp; to&nbsp; Uridisitol&nbsp; (antimuscarinic&nbsp; properties)&nbsp; or&nbsp; medicines with an opposite mode of action to Uridisitol (cholinergic properties). Ask your doctor if you are unsure. Please tell your doctor if you are taking or have recently taken any other</p><p>medicines, including medicines obtained without a prescription.</p><p>Uridisitol with food and drink</p><p>Uridisitol can be taken before, after or during a meal.</p><p>Pregnancy and breas t-feeding Pregnancy</p><p>You should not use Uridisitol when you are&nbsp; pregnant.&nbsp; Tell&nbsp; your&nbsp; doctor&nbsp; immediately&nbsp; if&nbsp; you&nbsp; are&nbsp; pregnant, think you are pregnant or are planning to become pregnant.</p><p>Breast-feeding</p><p>It is not known if tolterodine, the active substance of Uridisitol, is excreted in the mother&rsquo;s breast milk. Breast-feeding is not recommended during administration of Uridisitol.</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p>Driving&nbsp; and&nbsp; using machines</p><p>Uridisitol may make you feel dizzy, tired or affect your sight; your ability to drive or operate machinery may be affected.</p><p>Uridisitol contains sodium</p><p>Tolterodine contains less than 1&nbsp; mmol&nbsp; sodium&nbsp; (23&nbsp; mg)&nbsp; per&nbsp; 1&nbsp; mg and&nbsp; 2 mg film-coated&nbsp; tablets,&nbsp; that is to say essentially &lsquo;sodium- free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Dosage</p><p>&nbsp;</p><p>&nbsp;</p><p>Always take Uridisitol exactly as your doctor has&nbsp; told&nbsp; you.&nbsp; You&nbsp; should&nbsp; check&nbsp; with&nbsp; your doctor or pharmacist if you are not sure.</p><p>The usual dose is one 2 mg tablet twice daily, except&nbsp; for&nbsp; patients&nbsp; who&nbsp; have&nbsp; a&nbsp; kidney&nbsp; or&nbsp; a&nbsp; liver condition or troublesome side effects in which case your doctor may reduce&nbsp; your&nbsp; dose to&nbsp; one&nbsp; 1&nbsp; mg tablet twice daily.</p><p>Uridisitol is not recommended for children.</p><p>The tablets are for oral use and should be swa<strong>l </strong>owed whole.</p><p>Duration of treatment</p><p>Your doctor will tell you how long&nbsp; your treatment with Uridisitol will last. Do not stop treatment early because&nbsp; you do&nbsp; not&nbsp; see&nbsp; an immediate effect. Your bladder will need some time to adapt. Finish&nbsp;&nbsp;&nbsp; the course of tablets prescribed by your&nbsp; doctor.&nbsp; If you have&nbsp; not&nbsp; noticed&nbsp; any effect&nbsp; by then,&nbsp; talk to your doctor.</p><p>The benefit of the treatment should be re-evaluated after 2 or 3 months.</p><p>Always consult your doctor if you are thinking of stopping&nbsp; the treatment. If you take more Uridisitol than you should:</p><p>If you or somebody else takes too many tablets, contact your doctor or pharmacist immediately.</p><p>If you forget to take Uridisitol</p><p>If you forget to take a dose at the usual time,&nbsp; take&nbsp; it&nbsp; as soon as you remember&nbsp; unless&nbsp; it&nbsp; is&nbsp; almost&nbsp; time for your next dose. In that case, omit the forgotten dose and follow the normal dose schedule.</p><p>Do not take a double dose to make up for a forgotten one.</p><p>If you have any further questions on the use of this product, ask your doc tor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>like a<strong>l </strong>medicines, this medicine can cause side effects, although not everybody gets them.</p><p>you should see your&nbsp; doctor&nbsp; immediately or go&nbsp; to &nbsp;the&nbsp; casualty&nbsp; department&nbsp; if&nbsp; you&nbsp; experience symptoms of angioedema, such as:</p><p>&bull;&nbsp; swo<strong>l </strong>en face, tongue or pharynx</p><p>&bull;&nbsp; difficulty to swa<strong>l</strong><strong> </strong>ow</p><p>&bull;&nbsp; hives and difficulty in breathing</p><p>&nbsp;</p><p>&nbsp;</p><p>you should also seek medical attention if you experience a hypersensitivity reaction (for example itching, rash, hives, difficulty breathing).&nbsp; this&nbsp; occurs&nbsp;&nbsp; uncommonly&nbsp; (occurs&nbsp; in&nbsp; less&nbsp; than&nbsp; 1&nbsp; in&nbsp; 100&nbsp; patients).</p><p>te<strong>l </strong>your doctor immediately or go to the casualty department if you notice any of the following:</p><p>&bull;&nbsp; chest pain, difficulty breathing or getting tired easily (even at rest),&nbsp; difficulty&nbsp; breathing&nbsp; at night, swe<strong>l </strong>ing of the legs.</p><p>These may be symptoms of heart failure. this&nbsp; occurs&nbsp; uncommonly&nbsp; (occurs&nbsp; in&nbsp; less&nbsp; than&nbsp; 1&nbsp; in&nbsp; 100&nbsp; patients).</p><p>The following side effects have been&nbsp; observed&nbsp; during&nbsp; treatment&nbsp; with&nbsp; Uridisitol&nbsp; with the following frequencies.</p><p><strong>very common: </strong>may affect more than 1 in 10 people</p><p>&bull;&nbsp; dry mouth</p><p>&bull;&nbsp; headache</p><p><strong>common: </strong>may affect up to 1 in 10 people</p><p>&bull;&nbsp; bronchitis</p><p>&bull;&nbsp; dizziness, sleepiness, sensation of pins and needles in the fingers and toes</p><p>&bull;&nbsp; dry eyes, blurred vision</p><p>&bull;&nbsp; vertigo</p><p>&bull;&nbsp; palpitations</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; difficulty&nbsp; with&nbsp; digestion&nbsp; (dyspepsia),&nbsp; constipation,&nbsp; abdominal&nbsp; pain,&nbsp; excessive&nbsp; amounts&nbsp; of&nbsp; air&nbsp; or gases in the stomach or the intestine, vomiting</p><p>&bull;&nbsp; dry skin</p><p>&bull;&nbsp; painful or difficult urination, inability to empty the bladder</p><p>&bull;&nbsp; tiredness, chest pain, extra fluid in the body causing swe<strong>l </strong>ing (e.g. in the ankles)</p><p>&bull;&nbsp; increased weight</p><p>&bull;&nbsp; diarrhoea</p><p><strong>uncommon: </strong>may affect up to 1 in 100 people</p><p>&bull;&nbsp; a<strong>l </strong>ergic reactions</p><p>&bull;&nbsp; nervousness</p><p>&bull;&nbsp; increased heart rate, heart failure, irregular heartbeat</p><p>&nbsp;</p><p>&nbsp;</p><p>&bull;&nbsp; heart burn</p><p>&bull;&nbsp; memory impairment</p><p>Additional&nbsp; reactions&nbsp; reported&nbsp; include&nbsp;&nbsp; severe&nbsp;&nbsp; a<strong>l </strong>ergic&nbsp;&nbsp; reactions,&nbsp;&nbsp; confusion,&nbsp;&nbsp; ha<strong>l </strong>ucinations,&nbsp;&nbsp; flushed skin, angioedema&nbsp; and&nbsp; disorientation.&nbsp; there&nbsp; have&nbsp; also&nbsp; been&nbsp; reports&nbsp; of&nbsp; worsening&nbsp; symptoms&nbsp; of dementia in patients being treated for dementia.</p><p>Reporting of side effects</p><p>If you get any side&nbsp; effects,&nbsp; talk&nbsp; to&nbsp; your&nbsp; doctor or pharmacist. This includes any possible side effects&nbsp; not listed in this&nbsp; leaflet.&nbsp; By&nbsp; reporting&nbsp; side&nbsp; effects&nbsp; you&nbsp; can&nbsp; help&nbsp; provide&nbsp; more&nbsp; information&nbsp; on&nbsp; the&nbsp; safety of this medicine.</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse&nbsp; reactions&nbsp; after&nbsp; authorisation&nbsp; of the&nbsp; medicinal&nbsp; product is important. It a<strong>l </strong>ows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions (see details below)</p><p><u>Reporting of suspected adverse reactions</u></p><p>&bull;&nbsp;&nbsp; Saudi Arabia<em>:</em></p><p><strong><em>&nbsp;</em></strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
  margin-left:66.4pt;margin-top:11.05pt;width:409.5pt;height:114pt;z-index:-251653120;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f" strokeweight=".26494mm">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-left:10.45pt;line-height:12.35pt;
     mso-line-height-rule:exactly'>The National Pharmacovigilance and Drug
     Safety Centre (NPC)<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:.35pt'><span style='font-size:10.5pt;
     mso-bidi-font-size:12.0pt'><o:p>&nbsp;</o:p></span></p>
     <p class=MsoBodyText style='margin-left:22.45pt;text-indent:-9.05pt;
     mso-list:l2 level1 lfo1;tab-stops:22.5pt'><![if !supportLists]><span
     style='letter-spacing:-.75pt'><span style='mso-list:Ignore'>o<span
     style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
     dir=LTR></span>SFDA Ca<b style='mso-bidi-font-weight:normal'>l </b><span
     style='letter-spacing:-.2pt'>Center:</span><span style='letter-spacing:
     1.8pt'> </span>19999<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:.4pt'><span style='font-size:10.5pt;
     mso-bidi-font-size:12.0pt'><o:p>&nbsp;</o:p></span></p>
     <p class=MsoBodyText style='margin-left:19.45pt;text-indent:-9.05pt;
     mso-list:l2 level1 lfo1;tab-stops:19.5pt'><![if !supportLists]><span
     style='letter-spacing:-.75pt'><span style='mso-list:Ignore'>o<span
     style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
     dir=LTR></span><a href="mailto:npc.drug@sfda.gov.sa"><span
     style='color:blue;letter-spacing:-.15pt'>E-mail:npc.drug@sfda.gov.sa</span></a><o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:.55pt'><span style='font-size:11.0pt;
     mso-bidi-font-size:12.0pt'><o:p>&nbsp;</o:p></span></p>
     <p class=MsoBodyText style='margin-left:19.5pt;text-indent:-9.05pt;
     mso-list:l2 level1 lfo1;tab-stops:19.55pt'><![if !supportLists]><span
     style='letter-spacing:-.75pt'><span style='mso-list:Ignore'>o<span
     style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
     dir=LTR></span><span style='letter-spacing:-.15pt'>Website:https://ade.sfda.gov.sa/</span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="550" height="156" alt="Text Box: The National Pharmacovigilance and Drug Safety Centre (NPC)

o	SFDA Cal Center: 19999

o	E-mail:npc.drug@sfda.gov.sa

o	Website:https://ade.sfda.gov.sa/
" src="file:///C:/Users/Lenovo/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><strong>o Other GCC States:</strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store below 30&deg;C.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in the original package in order to protect from moisture.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep out of the reach and sight of children.</p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use Uridisitol after the&nbsp; expiry date&nbsp; which is&nbsp; stated&nbsp; on the&nbsp; pack.&nbsp; The&nbsp; expiry date&nbsp; refers to the last day of that month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use Uridisitol if you notice that the pack is damaged or shows signs of tampering.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines should not be disposed&nbsp; of&nbsp; via&nbsp; wastewater&nbsp; or&nbsp; household&nbsp; waste.&nbsp; Ask&nbsp; your&nbsp; pharmacist how to dispose of medicines no longer required. These measures wi<strong>l</strong><strong> </strong>help to &nbsp;protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a.&nbsp;&nbsp; </strong><strong>What </strong><strong>Uridisitol</strong><strong> </strong><strong>contains</strong></p><p><strong>Uridisitol :</strong></p><p>The active substance is Tolterodine tartrate.</p><p>Uridisitol (Tolterodine tartrate Tablets 2mg)</p><p>Each film coated tablet contains Tolterodine Tartrate 2mg.</p><p><strong>The&nbsp; </strong><strong>other&nbsp; ingredients&nbsp; are:&nbsp; </strong>Microcrysta<strong>l </strong>ine,&nbsp; Calcium&nbsp; Hydrogen&nbsp; Phosphate&nbsp; Dihydrate,&nbsp; Sodium starch glycolate, Silica colloidal anhydrous, Magnesium stearate.</p><p><strong>Film </strong><strong>coating</strong><strong> </strong><strong>composition: </strong>HPMC 2910/hyprome<strong>l </strong>ose, Purified stearic acid, Titanium Dioxide, microcrystalline cellulose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Uridisitol
White, round, biconvex, film coated tablets, debossed with 'J' on one side and '158' on the other side.
How supplied:
Uridisitol tablets are supplied in Blister pack.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>a.&nbsp;&nbsp;&nbsp; Marketing Authorisation Holder and Manufacturer Saudi Amarox</p><p><strong>Industrial Company</strong></p><p>Aljameah Street, Malaz District, Riyadh 12629, Saudi&nbsp; Arabia Tel: +966 11 226 8850</p><p><strong>Manufacture</strong>: Hetero Labs Limited Unit V, India.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                d.	This leaflet was last revised in October , 2023.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ﺎدة اﻟﻔﻌﺎﻟﺔ ﻓﻲ ﯾورﯾدﯾﺳﯾﺗول ھﻲ ﺗوﻟﺗﯾرودﯾن. ﯾﻧﺗﻣﻲ ﺗوﻟﺗﯾرودﯾن إﻟﻰ ﻣﺟﻣوﻋﺔ ﻣن اﻷدوﯾﺔ ﺗﺳﻣﻰ ﻣﺿﺎدات اﻟﻣﺳﻛﺎرﯾن.&nbsp;<br />ﯾﺳﺗﺧدم ﯾورﯾدﯾﺳﯾﺗول ﻟﻌﻼج أﻋراض ﻣﺗﻼزﻣﺔ ﻓرط ﻧﺷﺎط اﻟﻣﺛﺎﻧﺔ. إذا ﻛﻧت ﺗﻌﺎﻧﻲ ﻣن ﻣﺗﻼزﻣﺔ ﻓرط ﻧﺷﺎط اﻟﻣﺛﺎﻧﺔ ، ﻓﻘد ﺗﻌﺎﻧﻲ ﻣن ﻣﺎ ﯾﻠﻲ:</p><p>دم ﻗدرﺗك ﻋﻠﻰ اﻟﺗﺣﻛم ﻓﻲ اﻟﺗﺑول &nbsp;<br />ﺗﺣﺗﺎج إﻟﻰ اﻟذھﺎب إﻟﻰ اﻟﻣرﺣﺎض دون ﺳﺎﺑﻖ إﻧذار و / أو اﻟذھﺎب إﻟﻰ اﻟﻣرﺣﺎض ﺑﺷﻛل ﻣﺗﻛرر.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;ﻻ ﺗﺳﺗﺧدم ﯾورﯾدﯾﺳﯾﺗول أﻗراص</p><p>ا ﻛﻧت ﺗﻌﺎﻧﻲ ﻣن ﺣﺳﺎﺳﯾﺔ ﺗﺟﺎه ﺗوﻟﺗﯾرودﯾن ﺗﺎرﺗراﯾﺗﺄو أي ﻣن اﻟﻣﻛوﻧﺎت اﻷﺧرى ﻟﮭذا اﻟدواء )اﻟﻣدرﺟﺔ ﻓﻲ اﻟﻘﺳم ٦(.&nbsp;<br />إذا ﻛﻧت ﻏﯾر ﻗﺎدرة ﻋﻠﻰ إﺧراج اﻟﺑول ﻣن اﻟﻣﺛﺎﻧﺔ )اﺣﺗﺑﺎس اﻟﺑول(.<br />إذا ﻛﺎن ﺗﻌﺎﻧﻲ ﻣن اﻟﺟﻠوﻛوﻣﺎ )اﻟﻣﯾﺎه اﻟزرﻗﺎء ﻣﻧﻐﻠﻘﺔ اﻟزاوﯾﺔ( وﻟم ﯾﺗم ﻋﻼﺟﮭﺎ )ﺿﻐط ﻣرﺗﻔﻊ ﻓﻲ اﻟﻌﯾن ﻣﻊ ﻓﻘدان اﻟﺑﺻر اﻟذي ﻻ ﯾﺗم ﻋﻼﺟﮫ ﺑﺷﻛل ﻛﺎفٍ(.&nbsp;<br />إذا ﻛﻧت ﺗﻌﺎﻧﻲ ﻣن اﻟوھن اﻟﻌﺿﻠﻲ اﻟﺷدﯾد )ﺿﻌف ﻣﻔرط ﻓﻲ اﻟﻌﺿﻼت(.&nbsp;<br />إذا ﻛﻧت ﺗﻌﺎﻧﻲ ﻣن اﻟﺗﮭﺎب اﻟﻘوﻟون اﻟﺗﻘرﺣﻲ اﻟﺷدﯾد )ﺗﻘرح واﻟﺗﮭﺎب اﻟﻘوﻟون(. &nbsp;<br />إذا ﻛﻧت ﺗﻌﺎﻧﻲ ﻣن ﺗﺿﺧم اﻟﻘوﻟون اﻟﺳﺎم )ﺗوﺳﻊ ﺣﺎد ﻓﻲ اﻟﻘوﻟون(. &nbsp;</p><p>اﻟﺗﺣذﯾرات واﻻﺣﺗﯾﺎطﺎت</p><p>&nbsp;ﻛﻧت ﺗﻌﺎﻧﻲ ﻣن ﺻﻌوﺑﺎت ﻓﻲ اﻟﺗﺑول و / أو ﺿﻌف ﺗدﻓﻖ اﻟﺑول&nbsp;<br />إذا ﻛﻧت ﺗﻌﺎﻧﻲ ﻣن ﻣرض ﻣﻌدي ﻣﻌوي ﯾؤﺛر ﻋﻠﻰ ﻣرور و / أو ھﺿم اﻟطﻌﺎم &nbsp;إذا ﻛﻧت ﺗﻌﺎﻧﻲ ﻣن ﻣﺷﺎﻛل ﻓﻲ اﻟﻛﻠﻰ )ﻗﺻور ﻛﻠوي(. &nbsp;</p><p>&nbsp;ﻛﺎن ﻟدﯾك ﻣرض ﻓﻲ اﻟﻛﺑد&nbsp;<br />إذا ﻛﻧت ﺗﻌﺎﻧﻲ ﻣن اﺿطراﺑﺎت ﻋﺻﺑﯾﺔ ﺗؤﺛر ﻋﻠﻰ ﺿﻐط اﻟدم أو اﻷﻣﻌﺎء أو اﻟوظﯾﻔﺔ اﻟﺟﻧﺳﯾﺔ )أي اﻻﻋﺗﻼل اﻟﻌﺻﺑﻲ ﻓﻲ اﻟﺟﮭﺎز &nbsp;اﻟﻌﺻﺑﻲ اﻟﻼإرادي(.<br />إذا ﻛﺎن ﻟدﯾك ﻓﺗﻖ ﺣﺟﺎﺑﻲ )ﻓﺗﻖ ﻓﻲ أﺣد أﻋﺿﺎء اﻟﺑطن(.<br />إذا ﻋﺎﻧﯾت ﻓﻲ أي وﻗت ﻣن اﻧﺧﻔﺎض ﻓﻲ ﺣرﻛﺔ اﻷﻣﻌﺎء أو ﻛﻧت ﺗﻌﺎﻧﻲ ﻣن إﻣﺳﺎك ﺷدﯾد )اﻧﺧﻔض اﻟﺣرﻛﺔ اﻟﻣﻌوﯾﺔ اﻟﻣﻌوﯾﺔ(. إذا ﻛﻧت ﺗﻌﺎﻧﻲ ﻣن ﻣرض ﻓﻲ اﻟﻘﻠب ﻣﺛل:<br />ﺗﺗﺑﻊ ﻏﯾر طﺑﯾﻌﻲ ﻟﻠﻘﻠبECG)( . &nbsp;<br />ﺑطء ﻣﻌدل ﺿرﺑﺎت اﻟﻘﻠب )ﺑطء اﻟﻘﻠب(.&nbsp;<br />أﻣراض اﻟﻘﻠب اﻟﻣوﺟودة ﻣﺳﺑﻘﺎ ً ﻣﺛل:&nbsp;<br />اﻋﺗﻼل ﻋﺿﻠﺔ اﻟﻘﻠب ﺿﻌف ﻋﺿﻠﺔ اﻟﻘﻠب(<br />ﻧﻘص ﺗروﯾﺔ ﻋﺿﻠﺔ اﻟﻘﻠب )اﻧﺧﻔﺎض ﺗدﻓﻖ اﻟدم إﻟﻰ اﻟﻘﻠب(.&nbsp;<br />ﻋدم اﻧﺗظﺎم ﺿرﺑﺎت اﻟﻘﻠب&nbsp;<br />وﻓﺷل اﻟﻘﻠب&nbsp;<br />إذا ﻛﺎن ﻟدﯾك ﻣﺳﺗوﯾﺎت ﻣﻧﺧﻔﺿﺔ ﺑﺷﻛل ﻏﯾر طﺑﯾﻌﻲ ﻣن اﻟﺑوﺗﺎﺳﯾوم ﻓﻲ اﻟدم )ﻧﻘص ﺑوﺗﺎﺳﯾوم اﻟدم( أو اﻟﻛﺎﻟﺳﯾوم )ﻧﻘص ﻛﺎﻟﺳﯾوم اﻟدم( أو اﻟﻣﺎﻏﻧﯾﺳﯾوم ﻧﻘص ﻣﺎﻏﻧﺳﯾوم اﻟدم(.&nbsp;</p><p>ﺣدث إﻟﻰ طﺑﯾﺑك أو اﻟﺻﯾدﻟﻲ ﻗﺑل ﺑدء اﻟﻌﻼج ﺑﺎﺳﺗﺧدام ﯾورﯾدﯾﺳﯾﺗول إذا ﻛﻧت ﺗﻌﺗﻘد أن أﯾﺎ ً ﻣن ھؤﻻء ﻗد ﯾﻧطﺑﻖ ﻋﻠﯾك.&nbsp;</p><p>وﯾﺔ اﻷﺧرى و ﺗﻧﺎول ﯾورﯾدﯾﺳﯾﺗول أﻗراص&nbsp;<br />ﻗد ﯾﺗﻔﺎﻋل ﺗوﻟﺗﯾرودﯾن اﻟﻣﺎدة اﻟﻔﻌﺎﻟﺔ ﻓﻲ ﯾورﯾدﯾﺳﯾﺗول&quot; ﻣﻊ اﻟﻣﻧﺗﺟﺎت اﻟطﺑﯾﺔ اﻷﺧرى. ﻻ ﯾﻧﺻﺢ ﺑﺎﺳﺗﺧدام ﺗوﻟﺗﯾرودﯾن ﻣﻊ:&nbsp;</p><p>ض اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ )ﻣﺛل اﻹرﯾﺛروﻣﯾﺳﯾن واﻟﻛﻼرﯾﺛروﻣﯾﺳﯾن(. &nbsp;<br />اﻟﻣﻧﺗﺟﺎت اﻟطﺑﯾﺔ اﻟﻣﺳﺗﺧدﻣﺔ ﻟﻌﻼج اﻻﻟﺗﮭﺎﺑﺎت اﻟﻔطرﯾﺔ اﻟﺗﻲ ﺗﺣﺗوي ﻋﻠﻰ ﺳﺑﯾل اﻟﻣﺛﺎل ﻛﯾﺗوﻛوﻧﺎزول &nbsp;إﯾﺗراﻛوﻧﺎزول(. &nbsp;اﻷدوﯾﺔ اﻟﻣﺳﺗﺧدﻣﺔ ﻓﻲ ﻋﻼج ﻓﯾروس ﻧﻘص اﻟﻣﻧﺎﻋﺔ اﻟﺑﺷرﯾﺔ.&nbsp;</p><p>ﯾﺟب اﺳﺗﺧدام ﯾورﯾدﯾﺳﯾﺗول ﺑﺣذر ﻋﻧد ﺗﻧﺎوﻟﮫ ﻣﻊ:</p><p>دوﯾﺔ اﻟﺗﻲ ﺗؤﺛر ﻋﻠﻰ ﻣرور اﻟطﻌﺎم )اﻟﺗﻲ ﺗﺣﺗوي ﻋﻠﻰ ﺳﺑﯾل اﻟﻣﺛﺎل ﻣﯾﺗوﻛﻠوﺑراﻣﯾد وﺳﯾﺳﺎﺑرﯾد(.&nbsp;<br />اﻷدوﯾﺔ ﻟﻌﻼج ﻋدم اﻧﺗظﺎم ﺿرﺑﺎت اﻟﻘﻠب )اﻟﺗﻲ ﺗﺣﺗوي ﻋﻠﻰ ﺳﺑﯾل اﻟﻣﺛﺎل أﻣﯾودارون &nbsp;ﺳوﺗﺎﻟول &nbsp;ﻛﯾﻧﯾدﯾن &nbsp;ﺑروﻛﺎﯾﯾﻧﺎﻣﯾد(. اﻷدوﯾﺔ اﻷﺧرى اﻟﺗﻲ ﻟﮭﺎ ﻧﻔس ﺗﺄﺛﯾر ﯾورﯾدﯾﺳﯾﺗول )اﻟﺧﺻﺎﺋص اﻟﻣﺿﺎدة ﻟﻠﻣﺳﻛﺎرﯾن( أو اﻷدوﯾﺔ اﻟﺗﻲ ﻟﮭﺎ ﺗﺄﺛﯾر ﻣﻌﺎﻛس &nbsp;ﻟﻠﯾورﯾدﯾﺳﯾﺗول اﻟﺧﺻﺎﺋص اﻟﻛوﻟﯾﻧﯾﺔ(. اﺳﺄل طﺑﯾﺑك إذا ﻛﻧت ﻏﯾر ﻣﺗﺄﻛد.&nbsp;</p><p>ﯾرﺟﻰ إﺧﺑﺎر طﺑﯾﺑك إذا ﻛﻧت ﺗﺗﻧﺎول أو ﺗﻧﺎوﻟت ﻣؤﺧرً ا أي أدوﯾﺔ أﺧرى &nbsp;ﺑﻣﺎ ﻓﻲ ذﻟك اﻷدوﯾﺔ اﻟﺗﻲ ﺗم اﻟﺣﺻول ﻋﻠﯾﮭﺎ ﺑدون وﺻﻔﺔ طﺑﯾﺔ. ﺗﻧﺎول ﯾورﯾدﯾﺳﯾﺗول ﻣﻊ اﻟطﻌﺎم واﻟﺷراب &nbsp;<br />ﯾﻣﻛن ﺗﻧﺎول ﯾورﯾدﯾﺳﯾﺗول ﻗﺑل أو ﺑﻌد أو أﺛﻧﺎء اﻟوﺟﺑﺔ.&nbsp;<br />اﻟﺣﻣل واﻟرﺿﺎﻋﺔ&nbsp;<br />اﻟﺣﻣل &nbsp;<br />ﯾﺟب ﻋدم اﺳﺗﺧدام ﯾورﯾدﯾﺳﯾﺗول أﺛﻧﺎء اﻟﺣﻣل. أﺧﺑري طﺑﯾﺑك ﻋﻠﻰ اﻟﻔور إذا ﻛﻧت ﺣﺎﻣﻼ أً و ﺗﻌﺗﻘدﯾن أﻧك ﺣﺎﻣل أو ﺗﺧططﯾن ﻟﻠﺣﻣل. اﻟرﺿﺎﻋﺔ اﻟطﺑﯾﻌﯾﺔ&nbsp;<br />ﻣن ﻏﯾر اﻟﻣﻌروف إﻣﻛﺎﻧﯾﺔ إﻓراز اﻟﺗوﻟﺗﯾرودﯾن اﻟﻣﺎدة اﻟﻔﻌﺎﻟﺔ ﻓﻲ ﯾورﯾدﯾﺳﯾﺗول&quot; ﻓﻲ ﺣﻠﯾب اﻷم. ﻻ ﯾﻧﺻﺢ ﺑﺎﻟرﺿﺎﻋﺔ اﻟطﺑﯾﻌﯾﺔ أﺛﻧﺎء اﻟﻌﻼج ﺑﺎﺳﺗﺧدام ﯾورﯾدﯾﺳﯾﺗول.&nbsp;</p><p>ﺄل طﺑﯾﺑك أو اﻟﺻﯾدﻟﻲ ﻟﻠﺣﺻول ﻋﻠﻰ اﻟﻣﺷورة ﻗﺑل ﺗﻧﺎول أي دواء.&nbsp;<br />اﻟﻘﯾﺎدة واﺳﺗﺧدام اﻵﻻت&nbsp;<br />ﻗد ﯾﺟﻌﻠك ﯾورﯾدﯾﺳﯾﺗول ﺗﺷﻌر ﺑﺎﻟدوار أو اﻟﺗﻌب أو ﯾؤﺛر ﻋﻠﻰ ﺑﺻرك ؛ ﻗد ﺗﺗﺄﺛر ﻗدرﺗك ﻋﻠﻰ اﻟﻘﯾﺎدة أو ﺗﺷﻐﯾل اﻵﻻت. ﻣﺣﺗوي ﯾورﯾدﯾﺳﯾﺗول ﻣن اﻟﺻودﯾوم&nbsp;</p><p>ﺣﺗوي ﺗوﻟﺗﯾرودﯾن ﻋﻠﻰ أﻗل ﻣن ۱ ﻣﻠﻲ ﻣول ﺻودﯾوم )۲۳ ﻣﻠﺟرام ( ﻟﻛل ۱ ﻣﻠﺟرام &nbsp; و ۲ ﻣﻠﺟرام &nbsp;أﻗراص ﻣﻐﻠﻔﺔ ، وھذا ﯾﻌﻧﻲ ﺑﺷﻛل أﺳﺎﺳﻲ &quot;ﺧﺎﻟﻲ ﻣن اﻟﺻودﯾوم&quot;.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>رﻋﺔ&nbsp;<br />داﺋﻣﺎ ﺗﻧﺎول ﯾورﯾدﯾﺳﯾﺗول ﺗﻣﺎﻣﺎ ﻛﻣﺎ أﺧﺑرك طﺑﯾﺑك. ﯾﺟب ﻋﻠﯾك ﻣراﺟﻌﺔ طﺑﯾﺑك أو اﻟﺻﯾدﻟﻲ إذا ﻟم ﺗﻛن ﻣﺗﺄﻛدًا.</p><p>ﻟﺟرﻋﺔ اﻟﻣﻌﺗﺎدة ھﻲ ﻗرص واﺣد ۲ ﻣﻠﺟرام &nbsp;ﻣرﺗﯾن ﯾوﻣﯾﺎ ً ، ﺑﺎﺳﺗﺛﻧﺎء اﻟﻣرﺿﻰ اﻟذﯾن ﯾﻌﺎﻧون ﻣن أﻣراض اﻟﻛﻠﻰ أو اﻟﻛﺑد أو آﺛﺎر ﺟﺎﻧﺑﯾﺔ ﻣزﻋﺟﺔ ، وﻓﻲ ھذه اﻟﺣﺎﻟﺔ ﻗد ﯾﻘوم طﺑﯾﺑك ﺑﺗﻘﻠﯾل اﻟﺟرﻋﺔ إﻟﻰ ﻗرص &nbsp;۱ ﻣﻠﺟرام &nbsp;ﻣرﺗﯾن ﯾوﻣﯾﺎً رﯾدﯾﺳﯾﺗول ﻻ ﯾﻧﺻﺢ ﺑﮫ ﻟﻸطﻔﺎل.&nbsp;<br />اﻷﻗراص ﻟﻼﺳﺗﺧدام اﻟﻔﻣوي وﯾﺟب اﺑﺗﻼﻋﮭﺎ ﻛﺎﻣﻠﺔ. ﻣدة اﻟﻌﻼج &nbsp;</p><p>ﺳﯾﺧﺑرك طﺑﯾﺑك إﻟﻰ ﻣﺗﻰ ﺳﯾﺳﺗﻣر ﻋﻼﺟك ﺑﺎﺳﺗﺧدام ﯾورﯾدﯾﺳﯾﺗول. ﻻ ﺗﺗوﻗف ﻋن اﻟﻌﻼج ﻣﺑﻛرً ا ﻷﻧك ﻻ ﺗرى ﺗﺄﺛﯾرً ا ﻓورﯾﺎ. ً ﺳﺗﺣﺗﺎج ﻣﺛﺎﻧﺗك إﻟﻰ ﺑﻌض اﻟوﻗت ﻟﻠﺗﻛﯾف. ﻗم ﺑﺈﻧﮭﺎء دورة اﻷﻗراص اﻟﺗﻲ وﺻﻔﮭﺎ طﺑﯾﺑك. إذا ﻟم ﺗﻼﺣظ أي ﺗﺄﺛﯾر ﺑﺣﻠول ذﻟك اﻟوﻗت ، ﺗﺣدث إﻟﻰ طﺑﯾﺑك.</p><p>ب إﻋﺎدة ﺗﻘﯾﯾم ﻓﺎﺋدة اﻟﻌﻼج ﺑﻌد ﺷﮭرﯾن أو ﺛﻼﺛﺔ أﺷﮭر.&nbsp;<br />اﺳﺗﺷر طﺑﯾﺑك داﺋﻣًﺎ إذا ﻛﻧت ﺗﻔﻛر ﻓﻲ إﯾﻘﺎف اﻟﻌﻼج.&nbsp;<br />ﺗﻧﺎول ﺟرﻋﺔ زاﺋدة ﻣن ﯾورﯾدﯾﺳﯾﺗول أﻗراص&nbsp;<br />إذا ﺗﻧﺎوﻟت أﻧت أو أي ﺷﺧص آﺧر اﻟﻛﺛﯾر ﻣن اﻷﻗراص ، ﻓﺎﺗﺻل ﺑطﺑﯾﺑك أو اﻟﺻﯾدﻟﻲ ﻋﻠﻰ اﻟﻔور. إذا ﻧﺳﯾت أن ﺗﺗﻧﺎول ﯾورﯾدﯾﺳﯾﺗول &nbsp;أﻗراص&nbsp;</p><p>إذا ﻧﺳﯾت ﺗﻧﺎول ﺟرﻋﺔ ﻓﻲ اﻟوﻗت اﻟﻣﻌﺗﺎد ، ﻓﺗﻧﺎوﻟﮭﺎ ﺑﻣﺟرد أن ﺗﺗذﻛرھﺎ ﻣﺎ ﻟم ﯾﻛن اﻟوﻗت ﻗد ﺣﺎن ﻟﺟرﻋﺗك اﻟﺗﺎﻟﯾﺔ. ﻓﻲ ھذه اﻟﺣﺎﻟﺔ ، ﺗﺟﺎھل اﻟﺟرﻋﺔ اﻟﻣﻧﺳﯾﺔ واﺗﺑﻊ ﺟدول اﻟﺟرﻋﺔ اﻟﻣﻌﺗﺎد.&nbsp;</p><p>&nbsp;ﺗﺗﻧﺎول ﺟرﻋﺔ ﻣﺿﺎﻋﻔﺔ ﻟﺗﻌوﯾض اﻟﺟرﻋﺔ اﻟﻣﻧﺳﯾﺔ.&nbsp;<br />إذا ﻛﺎن ﻟدﯾك أي أﺳﺋﻠﺔ أﺧرى ﺣول اﺳﺗﺧدام ھذا اﻟدواء ، اﺳﺄل طﺑﯾﺑك أو اﻟﺻﯾدﻟﻲ</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>ل ﺟﻣﯾﻊ اﻷدوﯾﺔ ، ﯾﻣﻛن أن ﯾﺳﺑب ھذا اﻟدواء آﺛﺎرًا ﺟﺎﻧﺑﯾﺔ ، ﻋﻠﻰ اﻟرﻏم ﻣن ﻋدم ﺣدوﺛﮭﺎ ﻟدى اﻟﺟﻣﯾﻊ.&nbsp;<br />ﯾﺟب ﻋﻠﯾك ﻣراﺟﻌﺔ طﺑﯾﺑك ﻋﻠﻰ اﻟﻔور أو اﻟذھﺎب إﻟﻰ ﻗﺳم اﻟﻣﺻﺎﺑﯾن إذا ﻛﻧت ﺗﻌﺎﻧﻲ ﻣن أﻋراض اﻟوذﻣﺔ اﻟوﻋﺎﺋﯾﺔ ، ﻣﺛل</p><p>ﻧﺗﻔﺎخ اﻟوﺟﮫ أو اﻟﻠﺳﺎن أو اﻟﺑﻠﻌوم &nbsp;ﺻﻌوﺑﺔ اﻟﺑﻠﻊ&nbsp;<br />اﻟﺷرى وﺻﻌوﺑﺔ اﻟﺗﻧﻔس&nbsp;</p><p>ﯾﺟب ﻋﻠﯾك أﯾﺿًﺎ طﻠب اﻟﻌﻧﺎﯾﺔ اﻟطﺑﯾﺔ إذا ﻛﻧت ﺗﻌﺎﻧﻲ ﻣن ﺗﻔﺎﻋل ﻓرط اﻟﺣﺳﺎﺳﯾﺔ )ﻋﻠﻰ ﺳﺑﯾل اﻟﻣﺛﺎل اﻟﺣﻛﺔ واﻟطﻔﺢ اﻟﺟﻠدي واﻟﺷرى وﺻﻌوﺑﺔ اﻟﺗﻧﻔس(. ﯾﺣدث ھذا ﺑﺷﻛل ﻏﯾر ﺷﺎﺋﻊ )ﯾﺣدث ﻓﻲ أﻗل ﻣن ۱ ﻣن ﻛل ۱۰۰ ﻣرﯾض(. &nbsp;</p><p>ر طﺑﯾﺑك ﻋﻠﻰ اﻟﻔور أو اذھب إﻟﻰ ﻗﺳم اﻹﺻﺎﺑﺎت إذا ﻻﺣظت أﯾﺎ ً ﻣﻣﺎ ﯾﻠﻲ:&nbsp;<br />&bull; أﻟم ﻓﻲ اﻟﺻدر ، ﺻﻌوﺑﺔ ﻓﻲ اﻟﺗﻧﻔس أو اﻟﺗﻌب ﺑﺳﮭوﻟﺔ )ﺣﺗﻰ أﺛﻧﺎء اﻟراﺣﺔ( ، ﺻﻌوﺑﺔ ﻓﻲ اﻟﺗﻧﻔس ﻟﯾﻼً ، ﺗورم ﻓﻲ اﻟﺳﺎﻗﯾن.</p><p>ﻗد ﺗﻛون ھذه أﻋراض ﻟﻔﺷل اﻟﻘﻠب. ﯾﺣدث ھذا ﺑﺷﻛل ﻏﯾر ﺷﺎﺋﻊ )ﯾﺣدث ﻓﻲ أﻗل ﻣن ۱ ﻣن ﻛل ۱۰۰ ﻣرﯾض(. ﻟوﺣظت اﻷﻋراض اﻟﺟﺎﻧﺑﯾﺔ اﻟﺗﺎﻟﯾﺔ أﺛﻧﺎء اﻟﻌﻼج ﺑﯾورﯾدﯾﺳﯾﺗول ﺑﺎﻟﺗرددات اﻟﺗﺎﻟﯾﺔ.&nbsp;<br />ﺷﺎﺋﻌﺔ ﺟدًا: ﻗد ﺗظﮭر ﻟدى أﻛﺛر ﻣن &nbsp;۱ ﻣن ﻛل ۱۰ أﺷﺧﺎص&nbsp;</p><p>ﺟﻔﺎف اﻟﻔم&nbsp;<br />ﺻداع اﻟراس &nbsp;<br />ﺷﺎﺋﻌﺔ: ﻗد ﺗظﮭر ﻟدى ﺣﺗﻰ ۱ ﻣن ﻛل ۱۰ أﺷﺧﺎص&nbsp;</p><p>ﮭﺎب ﺷﻌﺑﻲ&nbsp;<br />&nbsp;إﺣﺳﺎس ﺑوﺧز ﻓﻲ أﺻﺎﺑﻊ اﻟﯾدﯾن واﻟﻘدﻣﯾن&nbsp;<br />&nbsp;ﺗﺷوش اﻟرؤﯾﺔ &nbsp;<br />اﻟدوار &nbsp;<br />اﻟﺧﻔﻘﺎن &nbsp;<br />ﺻﻌوﺑﺔ ﻓﻲ اﻟﮭﺿم ﻋﺳر اﻟﮭﺿم( &nbsp;إﻣﺳﺎك &nbsp;أﻟم ﺑطﻧﻲ &nbsp;ﻛﻣﯾﺎت ﻣﻔرطﺔ ﻣن اﻟﮭواء أو ﻏﺎزات ﻓﻲ اﻟﻣﻌدة أو اﻷﻣﻌﺎء &nbsp;ﻗﻲء ﺟﻔﺎف اﻟﺟﻠد &nbsp;<br />اﻟﺗﺑول اﻟﻣؤﻟم أو اﻟﺻﻌب &nbsp;وﻋدم اﻟﻘدرة ﻋﻠﻰ إﻓراغ اﻟﻣﺛﺎﻧﺔ&nbsp;<br />اﻟﺗﻌب وأﻟم ﻓﻲ اﻟﺻدر وزﯾﺎدة اﻟﺳواﺋل ﻓﻲ اﻟﺟﺳم ﻣﻣﺎ ﺗﺳﺑب ﻓﻲ ﺗورم )ﻋﻠﻰ ﺳﺑﯾل اﻟﻣﺛﺎل ﻓﻲ اﻟﻛﺎﺣﻠﯾن(.&nbsp;<br />زﯾﺎدة اﻟوزن&nbsp;<br />إﺳﮭﺎل&nbsp;</p><p>ﻏﯾر ﺷﺎﺋﻌﺔ: ﻗد ﺗظﮭر ﻟدى ﺣﺗﻰ ۱ ﻣن ﻛل ۱۰۰ ﺷﺧص</p><p>ﺳﺎﺳﯾﺔ&nbsp;<br />اﻟﻌﺻﺑﯾﺔ&nbsp;<br />زﯾﺎدة ﻣﻌدل ﺿرﺑﺎت اﻟﻘﻠب &nbsp;ﻗﺻور اﻟﻘﻠب &nbsp;ﻋدم اﻧﺗظﺎم ﺿرﺑﺎت اﻟﻘﻠب ﺣرﻗﺔ ﻣن اﻟﻣﻌدة &nbsp;<br />ﺿﻌف اﻟذاﻛرة &nbsp;</p><p>ﺗﺷﻣل اﻟﺗﻔﺎﻋﻼت اﻹﺿﺎﻓﯾﺔ اﻟﺗﻲ ﺗم اﻹﺑﻼغ ﻋﻧﮭﺎ ردود ﻓﻌل ﺗﺣﺳﺳﯾﺔ ﺷدﯾدة وﺗوھﺎن. ﻛﻣﺎ وردت ﺗﻘﺎرﯾر ﻋن ﺗﻔﺎﻗم أﻋراض اﻟﺧرف ﻟدى اﻟﻣرﺿﻰ اﻟذﯾن ﯾﻌﺎﻟﺟون ﻣن اﻟﺧرف</p><p>ﺑﻼغ ﻋن اﻵﺛﺎر اﻟﺟﺎﻧﺑﯾﺔ: &nbsp;<br />إن ﻛﺎن &nbsp;ﻟدﯾك أﻋراض &nbsp;ﺟﺎﻧﺑﯾﺔ أو ﻻﺣظت أﻋراض &nbsp;ﺟﺎﻧﺑﯾﺔ ﻏﯾر ﻣذﻛورة ﻓﻲ ھذه اﻟﻧﺷرة، &nbsp;ﻓﺿﻼً &nbsp;اﺑﻠﻎ اﻟطﺑﯾب أو اﻟﺻﯾدﻟﻲ</p><p>ﻟﻺﺑﻼغ ﺣول اﻷﻋراض اﻟﺟﺎﻧﺑﯾﺔ اﻟﺗﻲ ﻗد ﺗﺣدث ﯾرﺟﻰ اﻟﺗواﺻل ﻋﺑر اﻟﻌﻧﺎوﯾن اﻟﺗﺎﻟﯾﺔ:</p><p>ﻟﻺﺑﻼغ ﻋن اﻷﻋراض اﻟﺟﺎﻧﺑﯾﺔ&nbsp;</p><p>اﻟﻣﻣﻠﻛﺔ اﻟﻌرﺑﯾﺔ اﻟﺳﻌودﯾﺔ&nbsp;<br />&nbsp;اﻟﻣرﻛز اﻟوطﻧﻲ ﻟﻠﺗﯾﻘظ واﻟﺳﻼﻣﺔ اﻟدواﺋﯾﺔ &nbsp;<br />o ﻣرﻛز اﻻﺗﺻﺎل ﺑﺎﻟﮭﯾﺋﺔ اﻟﻌﺎﻣﺔ ﻟﻠﻐذاء واﻟدواء: 19999</p><p>npc.drug@sfda.gov.sa :اﻟﺑرﯾد اﻹﻟﻛﺗروﻧﻲ o https://ade.sfda.gov.saاﻟﻣوﻗﻊ اﻹﻟﻛﺗروﻧﻲ: &nbsp;</p><p>دول ﻣﺟﻠس اﻟﺗﻌﺎون اﻟﺧﻠﯾﺟﻲ اﻷﺧرى:</p><p>ﯾرﺟﻰ اﻻﺗﺻﺎل ﺑﺎﻟﺳﻠطﺔ اﻟﺻﺣﯾﺔ اﻟﻣﺧﺗﺻﺔ</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ظ ﻓﻲ درﺟﺔ ﺣرارة أﻗل ﻣن &nbsp;۳۰ &nbsp;درﺟﺔ ﻣﺋوﯾﺔ.&nbsp;<br />ﯾﺟب اﻟﺗﺧزﯾن ﻓﻲ اﻟﻌﻠﺑﺔ اﻷﺻﻠﯾﺔ ﻟﺣﻣﺎﯾﺗﮫ ﻣن اﻟرطوﺑﺔ.&nbsp;<br />اﺣﻔظ ھذا اﻟدواء ﺑﻌﯾدًا ﻋن رؤﯾﺔ وﻣﺗﻧﺎول أﯾدي اﻷطﻔﺎل.&nbsp;<br />ﻻ ﺗﺳﺗﺧدم ھذا اﻟدواء ﺑﻌد ﺗﺎرﯾﺦ اﻧﺗﮭﺎء اﻟﺻﻼﺣﯾﺔ اﻟﻣذﻛور ﻋﻠﻰ اﻟﻌﺑوة ﺑﻌد EXP. ﯾﺷﯾر ﺗﺎرﯾﺦ اﻧﺗﮭﺎء اﻟﺻﻼﺣﯾﺔ إﻟﻰ اﻟﯾوم &nbsp;اﻷﺧﯾر ﻣن اﻟﺷﮭر.&nbsp;<br />ﻻ ﺗﺳﺗﺧدم ﯾورﯾدﯾﺳﯾﺗول إذا ﻻﺣظت أن اﻟﻌﺑوة ﺗﺎﻟﻔﺔ أو ﺗظﮭر ﻋﻠﯾﮭﺎ ﻋﻼﻣﺎت اﻟﻌﺑث.&nbsp;<br />ﻻ ﺗﺗﺧﻠص ﻣن اﻷدوﯾﺔ ﻓﻲ ﻣﯾﺎه اﻟﺻرف اﻟﺻﺣﻲ أو اﻟﻧﻔﺎﯾﺎت اﻟﻣﻧزﻟﯾﺔ. اﺳﺄل اﻟﺻﯾدﻟﻲ ﻋن ﻛﯾﻔﯾﺔ اﻟﺗﺧﻠص ﻣن اﻷدوﯾﺔ اﻟﺗﻲ ﻟم ﺗﻌد ﺑﺣﺎﺟﺔ إﻟﯾﮭﺎ. ﺳﺗﺳﺎﻋد ھذه اﻹﺟراءات ﻓﻲ ﺣﻣﺎﯾﺔ اﻟﺑﯾﺋﺔ.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ﺣﺗوي ﯾورﯾدﯾﺳﯾﺗول أﻗراص &nbsp;ﻋﻠﻰ: &nbsp;<br />اﻟﻣﺎدة اﻟﻔﻌﺎﻟﺔ ھﻲ ﺗوﻟﺗﯾرودﯾن طرطرات.&nbsp;<br />ﯾورﯾدﯾﺳﯾﺗول أﻗراص ﺗوﻟﺗﯾرودﯾن ﺗﺎرﺗراﯾت ۲ ﻣﻠﺟرام ﯾﺣﺗوي ﻛل ﻗرص ﻣﻐﻠف ﻋﻠﻰ ﺗوﻟﺗﯾرودﯾن ﺗﺎرﺗراﯾت ۲ ﻣﻠﺟرا</p><p>اﻟﺻواﻏﺎت اﻷﺧرى ھﻲ: ﺳﯾﻠﯾﻠوز دﻗﯾﻖ اﻟﺗﺑﻠور &nbsp;ھﯾدروﺟﯾن ﻓوﺳﻔﺎت اﻟﻛﺎﻟﺳﯾوم ﺛﻧﺎﺋﻲ اﻟﮭﯾدرات &nbsp;ﻧﺷﺎ اﻟﺻودﯾوم ﺟﻼﯾﻛوﻻت &nbsp;اﻟﺳﯾﻠﯾﻛﺎ اﻟﻐروﯾﺔ اﻟﻼﻣﺎﺋﯾﺔ ٰ &nbsp;ﺳﺗﯾرات اﻟﻣﺎﻏﻧﯾﺳﯾوم.&nbsp;<br />اﻟﺻواﻏﺎت اﻷﺧرى ﻟطﺑﻘﺔ اﻟﻛﺳوة اﻟﺧﺎرﺟﯾﺔ: ھﯾﺑرﻣﯾﻠوز &nbsp;HPMC 2910 ، ﺣﻣض دھﻧﻲ ﻣﻧﻘﻰ &nbsp;ﺛﺎﻧﻲ أﻛﺳﯾد اﻟﺗﯾﺗﺎﻧﯾوم &nbsp;ﺳﻠﯾﻠوز دﻗﯾﻖ &nbsp;اﻟﺗﺑﻠور.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>ﻣﺎ ھو ﺷﻛل ﯾورﯾدﯾﺳﯾﺗول أﻗراص؟</p><p>أﻗراص ﺑﯾﺿﺎء ، ﻣﺳﺗدﯾرة ، ﻣﺣدﺑﺔ ﻣن اﻟﺟﺎﻧﺑﯾن ، ﻣﻐﻠﻔﺔ ﺑطﺑﻘﺔ رﻗﯾﻘﺔ ، ﻣدﻣوغ ﻋﻠﯾﮭﺎ ﺣرف &quot;&quot;J ﻋﻠﻰ ﺟﺎﻧب واﺣد و &quot;۱٥۸&quot; ﻋﻠﻰ اﻟﺟﺎﻧب اﻵﺧر.&nbsp;</p><p>ﻔﯾﺔ ﺗوﻓﯾر ﯾورﯾدﯾﺳﯾﺗول أﻗراص؟&nbsp;<br />ﺗﺣﺗوي ﻋﺑوة ﯾورﯾدﯾﺳﯾﺗول ۲ ﻣﻠﺟرام أﻗراص ﻋﻠﻰ ﺷراﺋط ﺑﮭﺎ ۳ &nbsp;X &nbsp; ۱۰ أﻗراص</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>اﺳم وﻋﻧوان ﻣﺎﻟك رﺧﺻﺔ اﻟﺗﺳوﯾﻖ واﻟﻣﺻﻧﻊ ﺻﺎﺣب ﺣﻖ اﻟﺗﺳوﯾﻖ:&nbsp;<br />ﺷرﻛﺔ اﻣﺎروﻛس &nbsp;اﻟﺳﻌودﯾﺔ اﻟﺻﻧﺎﻋﯾﺔ ﺷﺎرع اﻟﺟﺎﻣﻌﺔ ، ﺣﻲ اﻟﻣﻠز &nbsp;&nbsp;<br />اﻟرﯾﺎض ۱۲٦۲۹ ، اﻟﻣﻣﻠﻛﺔ اﻟﻌرﺑﯾﺔ اﻟﺳﻌودﯾﺔ&nbsp;</p><p>+966 11 226 8850 :ھﺎﺗف و ﻓﺎﻛس</p><p>ﺻﻧﻊ &nbsp;<br />ﺷرﻛﺔ ھﺗﯾرو ﻻب اﻟﻣﺣدودة، اﻟوﺣدة اﻟﺧﺎﻣﺳﺔ ، اﻟﮭﻧد.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             ﻣراﺟﻌﺔ ھذه  اﻟﻧﺷرة ﻓﻲ اﻛﺗوﺑر ۲۰۲۳, ﻧﺳﺧﺔ  ۱
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Uridisitol (Tolterodine tartrate Tablets 2mg)
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film coated tablet contains Tolterodine Tartrate 2mg. Excipient(s) with known effect
For full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Uridisitol (Tolterodine tartrate Tablets 2mg)
White, round, biconvex, film coated tablets, debossed with 'J' on one side and '158' on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adults (including elderly: The recommended dose is 2 mg twice daily except in patients with impaired liver function or severely impaired renal function (GFR &lt;30 ml/min) for whom the recommended dose is 1 mg twice daily (see section 4.4). In case of troublesome side effects the dose may be reduced from 2 mg to 1 mg twice daily.</p><p>The effect of treatment should be re-evaluated after 2-3 months (see section 5.1). Paediatric population</p><p>Efficacy of Uridisitol has not been demonstrated in children (section 5.1). Therefore, Uridisitol is not recommended for children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tolterodine is contraindicated in patients with
-	Urinary retention
-	Uncontrolled narrow angle glaucoma
 
-	Myasthenia gravis
-	Known hypersensitivity to tolterodine or excipients (see section 6)
-	Severe ulcerative colitis
-	Toxic megacolon

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tolterodine shall be used with caution in patients with</p><p>-&nbsp; Significant bladder outlet obstruction at risk of urinary retention</p><p>-&nbsp; Gastrointestinal obstructive disorders, e.g. pyloric stenosis</p><p>-&nbsp; Renal impairement (see section 4.2)</p><p>-&nbsp; Hepatic disease. (see section 4.2 and 5.2)</p><p>-&nbsp; Autonomic neuropathy</p><p>-&nbsp; Hiatus hernia</p><p>-&nbsp; Risk for decreased gastrointestinal motility</p><p>Multiple oral total daily doses of immediate release 4 mg (therapeutic) and 8 mg (supratherapeutic) tolterodine have been shown to prolong the QTc interval (see section 5.1). The clinical relevance of these findings is unclear and will depend on individual patient risk factors and susceptibilities present.</p><p>Tolterodine should be used with caution in patients with risk factors for QT-prolongation including:</p><p>-&nbsp; Congenital or documented acquired QT prolongation</p><p>-&nbsp; Electrolyte disturbances such as hypokalaemia, hypomagnesaemia and hypocalcaemia</p><p>-&nbsp; Bradycardia</p><p>-&nbsp; Relevant pre-existing cardiac diseases (i.e. cardiomyopathy, myocardial ischaemia, arrhythmia, congestive heart failure)</p><p>-&nbsp; Concomitant administration of drugs known to prolong QT-interval including Class IA (e. g. quinidine, procainamide) and Class III (e. g. amiodarone, sotalol) anti-arrhythmics</p><p>This especially holds true when taking potent CYP3A4 inhibitors (see section 5.1). Concomitant treatment with potent CYP3A4 inhibitors should be avoided (see section 4.5). Urinary retention</p><p>&nbsp;</p><p>As with all treatments for symptoms of urgency and urge incontinence, organic reasons for urge and frequency should be considered before treatment.</p><p><u>Excipient information</u></p><p>Uridisitol 2 mg film-coated tablets contain less than 1 mmol sodium (23 mg) per tablet. Patients on low sodium diets can be informed that this medicinal product is essentially &#39;sodium-free&#39;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Concomitant systemic medication with potent CYP3A4 inhibitors such as macrolide antibiotics (e.g. erythromycin and clarithromycin), antifungal agents (e.g. ketoconazole and itraconazole) and antiproteases is not recommended due to increased serum concentrations of tolterodine in poor CYP2D6 metabolisers with (subsequent) risk of overdosage (see section 4.4).</p><p>Concomitant medication with other drugs that possess antimuscarinic properties may result in more pronounced therapeutic effect and side-effects. Conversely, the therapeutic effect of tolterodine may be reduced by concomitant administration of muscarinic cholinergic receptor agonists.</p><p>The effect of prokinetics like metoclopramide and cisapride may be decreased by tolterodine. Concomitant treatment with fluoxetine (a potent CYP2D6 inhibitor) does not result in a clinically significant interaction since tolterodine and its CYP2D6-dependent metabolite, 5- hydroxymethyl tolterodine are equipotent.</p><p>Drug interaction studies have shown no interactions with warfarin or combined oral contraceptives (ethinyl estradiol/levonorgestrel).</p><p>A clinical study has indicated that tolterodine is not a metabolic inhibitor of CYP2D6, 2C19, 2C9, 3A4 or 1A2. Therefore an increase of plasma levels of drugs metabolised by these isoenzymes is not expected when dosed in combination with tolterodine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1.1&nbsp;&nbsp; Pregnancy</p><p>There are no adequate data from the use of tolterodine in pregnant women.</p><p>Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown.</p><p>Consequently, Uridisitol is not recommended during pregnancy.</p><p>&nbsp;</p><p>Breast-feeding</p><p>No data concerning the excretion of tolterodine into human milk are available. Tolterodine should be avoided during lactation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Since this drug may cause accommodation disturbances and influence reaction time, the ability to drive and use machines may be negatively affected.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>Due to the pharmacological effect of tolterodine it may cause mild to moderate antimuscarinic effects, like dryness of the mouth, dyspepsia and dry eyes.</p><p>Table 1 below reflects the data obtained with Uridisitol in clinical trials and from postmarketing experience. The most commonly reported adverse reaction was dry mouth, which occurred in 35% of patients treated with Uridisitol tablets and in 10% of placebo treated patients. Headaches were also reported very commonly and occurred in 10.1% of patients treated with Uridisitol tablets and in 7.4% of placebo treated patients.</p><p><u>Tabulated list of adverse reactions</u></p><p>The adverse drug reactions listed in the table below are presented by System Organ Class (SOC) and frequency categories, defined using the following convention: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000), or not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>Table 1: Adverse drug reactions</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Very Common </strong>(&ge;1/10)</p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p>(&ge;1/100 to &lt;1/10)</p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p>(&ge;1/1000 to &lt;1/100)</p></td><td style="vertical-align:top"><p><strong>Not known </strong>(cannot be estimated from the available data)</p></td></tr><tr><td style="vertical-align:top"><p>Infections&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and infestations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Bronchitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; system</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity not</p></td><td style="vertical-align:top"><p>Anaphylactoid</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>otherwise specified</p></td><td style="vertical-align:top"><p>reactions</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Nervousness</p></td><td style="vertical-align:top"><p>Confusion, hallucinations, disorientation</p></td></tr><tr><td style="vertical-align:top"><p>Nervous&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; system disorders</p></td><td style="vertical-align:top"><p>Headaches</p></td><td style="vertical-align:top"><p>Dizziness, somnolence, paresthesia</p></td><td style="vertical-align:top"><p>Memory impairment</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dry eyes, abnormal vision&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; including abnormal accommodation</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Ear&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; labyrinth disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vertigo</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Palpitations</p></td><td style="vertical-align:top"><p>Tachycardia, cardiac failure, arrhythmia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Flushing</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Dry mouth</p></td><td style="vertical-align:top"><p>Dyspepsia, constipation, abdominal&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain, flatulence, vomiting, diarrhoea</p></td><td style="vertical-align:top"><p>Gastroesophageal reflux</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dry skin</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Angioedema</p></td></tr><tr><td style="vertical-align:top"><p>Renal&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; urinary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dysuria,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; urinary retention</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Fatigue, chest pain,</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>administration&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; site conditions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>peripheral oedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Increased weight</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>Cases of aggravation of symptoms of dementia (e.g. confusion, disorientation, delusion) have been reported after tolterodine therapy was initiated in patients taking cholinesterase inhibitors for the treatment of dementia.</p><p>Paediatric population In two paediatric phase III randomised, placebo-controlled, double-blind studies conducted over 12 weeks where a total of 710 paediatric patients were recruited, the proportion of patients with urinary tract infections, diarrhoea and abnormal behaviour was higher in patients treated with tolterodine than placebo (urinary tract infection: tolterodine 6.8 %, placebo 3.6 %; diarrhoea: tolterodine 3.3 %, placebo 0.9 %; abnormal behaviour: tolterodine 1.6</p><p>%, placebo 0.4 %). (See section 5.1)</p><p><strong><u>Reporting of suspected adverse reactions</u></strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>&bull;&nbsp; Saudi Arabia<em>:</em></p><p><strong><em>&nbsp;</em></strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
  margin-left:84.6pt;margin-top:9.55pt;width:402.45pt;height:106.95pt;
  z-index:-251656192;mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f" strokeweight=".48pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:0in;margin-right:81.75pt;
     margin-bottom:0in;margin-left:13.3pt;margin-bottom:.0001pt;text-indent:
     -3.0pt;line-height:193%'>The National Pharmacovigilance and Drug Safety
     Centre (NPC) o SFDA Call Center: 19999<o:p></o:p></p>
     <p class=MsoBodyText style='margin-left:19.3pt;text-indent:-9.2pt;
     line-height:13.7pt;mso-line-height-rule:exactly;mso-list:l0 level1 lfo1;
     tab-stops:19.35pt'><![if !supportLists]><span style='mso-list:Ignore'>o<span
     style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><![endif]><span
     dir=LTR></span><a href="mailto:npc.drug@sfda.gov.sa"><span
     style='color:windowtext;text-decoration:none;text-underline:none'>E-mail:npc.drug@sfda.gov.sa</span></a><o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:.5pt;margin-right:0in;margin-bottom:
     0in;margin-left:0in;margin-bottom:.0001pt'><span style='font-size:11.5pt;
     mso-bidi-font-size:12.0pt'><o:p>&nbsp;</o:p></span></p>
     <p class=MsoBodyText style='margin-left:19.3pt;text-indent:-9.2pt;
     mso-list:l0 level1 lfo1;tab-stops:19.35pt'><![if !supportLists]><span
     style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;
     </span></span><![endif]><span dir=LTR></span>Website:https://ade.sfda.gov.sa/<o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="541" height="147" alt="Text Box: The National Pharmacovigilance and Drug Safety Centre (NPC) o SFDA Call Center: 19999
o	E-mail:npc.drug@sfda.gov.sa

o	Website:https://ade.sfda.gov.sa/
" src="file:///C:/Users/Lenovo/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p><strong><em>&nbsp;</em></strong></p><p><strong>o Other GCC States:</strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The highest dose given to human volunteers of tolterodine L-tartrate is 12.8 mg as a single dose. The most severe adverse events observed were accommodation disturbances and micturition difficulties.</p><p>In the event of tolterodine overdose, treat with gastric lavage and give activated charcoal. Treat symptoms as follows:</p><p>-&nbsp;&nbsp;&nbsp; Severe central anticholinergic effects (e.g. hallucinations, severe excitation): treat with physostigmine</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Convulsions or pronounced excitation: treat with benzodiazepines</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Respiratory insufficiency: treat with artificial respiration</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Tachycardia: treat with beta-blockers</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Urinary retention: treat with catheterization</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Mydriasis: treat with pilocarpine eye drops and/or place patient in dark room</p><p>An increase in QT interval was observed at a total daily dose of 8 mg immediate release tolterodine (twice the recommended daily dose of the immediate release formulation and equivalent to three times the peak exposure of the prolonged release capsule formulation) administered over four days. In the event of tolterodine overdose, standard supportive measures for managing QT prolongation should be adopted.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5.0&nbsp; </strong>Pharmacotherapeutic group: Urinary antispasmodics ATC code: G04B D07</p><p>Mechanism of action</p><p>Tolterodine is a competitive, specific muscarinic receptor antagonist with a selectivity for the urinary bladder over salivary glands in vivo.</p><p><u>Pharmacodynamic effects</u></p><p>One of the tolterodine metabolites (5-hydroxymethyl derivative) exhibits a pharmacological profile similar to that of the parent compound. In extensive metabolisers this metabolite contributes significantly to the therapeutic effect (see section 5.2).</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p>Effect of the treatment can be expected within 4 weeks.</p><p>Effect of treatment with Uridisitol 2 mg twice daily after 4 and 12 weeks, respectively, compared with placebo (pooled data). Absolute change and percentage change relative to baseline.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Variable</p></td><td colspan="3" style="vertical-align:top"><p>4-week studies</p></td><td colspan="3" style="vertical-align:top"><p>12-week studies</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uridisitol 2 mg b.i.d.</p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>Statistical significance vs. placebo</p></td><td style="vertical-align:top"><p>Uridisitol 2 mg b.i.d.</p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>Statistical significance vs. placebo</p></td></tr><tr><td style="vertical-align:top"><p>Number of micturitions per 24 hours</p></td><td style="vertical-align:top"><p>-1.6</p><p>(-14%) n=392</p></td><td style="vertical-align:top"><p>-0.9</p><p>(-8%) n=189</p></td><td style="vertical-align:top"><p>*</p></td><td style="vertical-align:top"><p>-2.3</p><p>(-20%) n=354</p></td><td style="vertical-align:top"><p>-1.4</p><p>(-12%) n=176</p></td><td style="vertical-align:top"><p>**</p></td></tr><tr><td style="vertical-align:top"><p>Number&nbsp;&nbsp;&nbsp;&nbsp; of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; incontinence episodes per 24 hours</p></td><td style="vertical-align:top"><p>-1.3</p><p>(-38%) n=288</p></td><td style="vertical-align:top"><p>-1.0</p><p>(-26%) n=151</p></td><td style="vertical-align:top"><p>n.s.</p></td><td style="vertical-align:top"><p>-1.6</p><p>(-47%) n=299</p></td><td style="vertical-align:top"><p>-1.1</p><p>(-32%) n=145</p></td><td style="vertical-align:top"><p>*</p></td></tr><tr><td style="vertical-align:top"><p>Mean&nbsp;&nbsp; volume&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; voided&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per micturition (ml)</p></td><td style="vertical-align:top"><p>+25</p><p>(+17%) n=385</p></td><td style="vertical-align:top"><p>+12</p><p>(+8%) n=185</p></td><td style="vertical-align:top"><p>***</p></td><td style="vertical-align:top"><p>+35</p><p>(+22%) n=354</p></td><td style="vertical-align:top"><p>+10</p><p>(+6%) n=176</p></td><td style="vertical-align:top"><p>***</p></td></tr><tr><td style="vertical-align:top"><p>Number of patients with no or minimal bladder problems after treatment (%)</p></td><td style="vertical-align:top"><p>16% n=394</p></td><td style="vertical-align:top"><p>7% n=190</p></td><td style="vertical-align:top"><p>**</p></td><td style="vertical-align:top"><p>19% n=356</p></td><td style="vertical-align:top"><p>15% n=177</p></td><td style="vertical-align:top"><p>n.s.</p></td></tr></tbody></table><p>n.s.=not significant; *=p<u>&lt;</u>0.05; **= p<u>&lt;</u>0.01; ***= p<u>&lt;</u>0.001</p><p>&nbsp;</p><p>The effect of tolterodine was evaluated in patients, examined with urodynamic assessment at baseline and, depending on the urodynamic result, they were allocated to a urodynamic positive (motor urgency) or a urodynamic negative (sensory urgency) group. Within each group, the patients were randomised to receive either tolterodine or placebo. The study could not provide convincing evidence that tolterodine had effects over placebo in patients with sensory urgency.</p><p>&nbsp;</p><p>The clinical effects of tolterodine on QT interval were studied in ECGs obtained from over 600 treated patients, including the elderly and patients with pre-existing cardiovascular disease. The changes in QT intervals did not significantly differ between placebo and treatment groups.</p><p>The effect of tolterodine on QT-prolongation was investigated further in 48 healthy male and female volunteers aged 18-55 years. Subjects were administered 2 mg BID and 4 mg BID tolterodine as the immediate release formulations. The results (Fridericia corrected) at peak tolterodine concentration (1 hour) showed mean QTc interval increases of 5.0 and 11.8 msec for tolterodine doses of 2 mg BID and 4 mg BID respectively and 19.3 msec for moxifloxacin (400 mg) which was used as an active, internal control. A pharmacokinetic/pharmacodynamic model estimated that QTc interval increases in poor metabolisers (devoid of CYP2D6) treated with tolterodine 2 mg BID are comparable to those observed in extensive metabolisers receiving 4 mg BID. At both doses of tolterodine, no subject, irrespective of their metabolic profile, exceeded 500 msec for absolute QTcF or 60 msec for change from baseline that are considered thresholds of particular concern. The 4 mg BID dose corresponds to a peak exposure (Cmax) of three times that obtained with the highest therapeutic dose of Uridisitol XL capsules.</p><p>Paediatric population</p><p>Efficacy in the paediatric population has not been demonstrated. Two paediatric phase 3 randomised, placebocontrolled, double-blind 12 week studies were conducted using tolterodine extended release capsules. A total of 710 paediatric patients (486 on tolterodine and 224 on placebo) aged 5-10 years with urinary frequency and urge urinary incontinence were studied. No significant difference between the two groups was observed in either study with regard</p><p>to change from baseline in total number of incontinence episodes/week. (See section 4.8)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacokinetic characteristics specific for this formulation : Tolterodine is rapidly absorbed. Both tolterodine and the 5-hydroxymethyl metabolite reach maximal serum concentrations 1-3 hours after dose. The half-life for tolterodine given as the tablet is 2-3 hours in extensive and about 10 hours in poor metabolisers (devoid of CYP2D6). Steady state concentrations are reached within 2 days after administration of the tablets.</p><p>&nbsp;</p><p>Food does not influence the exposure to the unbound tolterodine and the active 5-hydroxymethyl metabolite in extensive metabolisers, although the tolterodine levels increase when taken with food. Clinically relevant changes are likewise not expected in poor metabolisers.</p><p>Absorption</p><p>After oral administration tolterodine is subject to CYP2D6 catalysed first-pass metabolism in the liver, resulting in the formation of the 5-hydroxymethyl derivative, a major pharmacologically equipotent metabolite.</p><p>The absolute bioavailability of tolterodine is 17 % in extensive metabolisers, the majority of the patients, and 65% in poor metabolisers (devoid of CYP2D6).</p><p>Distribution</p><p>Tolterodine and the 5-hydroxymethyl metabolite bind primarily to orosomucoid. The unbound fractions are 3.7% and 36%, respectively. The volume of distribution of tolterodine is 113 l.</p><p>Elimination</p><p>Tolterodine is extensively metabolised by the liver following oral dosing. The primary metabolic route is mediated by the polymorphic enzyme CYP2D6 and leads to the formation of the 5- hydroxymethyl metabolite. Further metabolism leads to formation of the 5-carboxylic acid and N-dealkylated 5-carboxylic acid metabolites, which account for 51 % and 29 % of the metabolites recovered in the urine, respectively. A subset (about 7%) of the population is devoid of CYP2D6 activity. The identified pathway of metabolism for these individuals (poor metabolisers) is dealkylation via CYP3A4 to N-dealkylated tolterodine, which does not contribute to the clinical effect. The remainder of the population is referred to as extensive metabolisers. The systemic clearance of tolterodine in extensive metabolisers is about 30</p><p>L/h. In poor metabolisers the reduced clearance leads to significantly higher serum concentrations of tolterodine (about 7-fold) and negligible concentrations of the 5- hydroxymethyl metabolite are observed. The 5-hydroxymethyl metabolite is pharmacologically active and equipotent with tolterodine. Because of the differences in the protein-binding characteristics of tolterodine and the 5-hydroxymethyl metabolite, the exposure (AUC) of unbound tolterodine in poor metabolisers is similar to the combined exposure of unbound tolterodine and the 5-hydroxymethyl metabolite in patients with CYP2D6 activity given the same</p><p>&nbsp;</p><p>dosage regimen. The safety, tolerability and clinical response are similar irrespective of phenotype.</p><p>The excretion of radioactivity after administration of [14C]-tolterodine is about 77% in urine and 17% in faeces. Less than 1% of the dose is recovered as unchanged drug, and about 4% as the 5- hydroxymethyl metabolite. The carboxylated metabolite and the corresponding dealkylated metabolite account for about 51% and 29% of the urinary recovery, respectively.</p><p>The pharmacokinetics is linear in the therapeutic dosage range.</p><p><u>Hepatic impairment</u> Impaired liver function: About 2-fold higher exposure of unbound tolterodine and the 5-hydroxymethyl metabolite is found in subjects with liver cirrhosis (see section 4.2 and 4.4).</p><p>Impaired renal function: The mean exposure of unbound tolterodine and its 5-hydroxymethyl metabolite is doubled in</p><p>patients with severe renal impairment (inulin clearance GFR &le; 30 ml/min). The plasma levels of other metabolites were markedly (up to 12-fold) increased in these patients. The clinical relevance of the increased exposure of these metabolites is unknown. There is no data in mild to moderate renal impairment (see section 4.2 and 4.4).</p><p>Paediatric population</p><p>The exposure of the active moiety per mg dose is similar in adults and adolescents. The mean exposure of the active moiety per mg dose is approximately two-fold higher in children between 5-10 years than in adults (See sections 4.2 and 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In toxicity, genotoxicity, carcinogenicity and safety pharmacology studies no clinically relevant effects have been observed, except those related to the pharmacological effect of the drug.</p><p>Reproduction studies have been performed in mice and rabbits.</p><p>In mice, there was no effect of tolterodine on fertility or reproductive function. Tolterodine produced embryo death and malformations at plasma exposures (Cmax or AUC) 20 or 7 times higher than those seen in treated humans.</p><p>In rabbits, no malformative effect was seen, but the studies were conducted at 20 or 3 times higher plasma exposure (Cmax or AUC) than those expected in treated humans.</p><p>&nbsp;</p><p>Tolterodine, as well as its active human metabolites prolong action potential duration (90% repolarization) in canine purkinje fibres (14 - 75 times therapeutic levels) and block the K+- current in cloned human ether-a-go-go-related gene (hERG) channels (0.5 &ndash; 26.1 times therapeutic levels). In dogs prolongation of the QT interval has been observed after application of tolterodine and its human metabolites (3.1 &ndash; 61.0 times therapeutic levels). The clinical relevance of these findings is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Tolterodine tartrate Tablets 2mg</strong></p><p><strong>The other ingredients are: </strong>Cellulose Microcrystalline, Calcium Hydrogen Phosphate Dihydrate, Sodium starch glycolate (Explotab Low pH), Silica colloidal anhydrous, Magnesium stearate.</p><p><strong>Film coating composition: </strong>HPMC 2910/hypromellose, Purified stearic acid, Titanium Dioxide, microcrystalline cellulose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 Years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>3x10 Alu-Alu blister.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste material should be disposed of in accordance with local Requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Saudi Amarox Industrial Company, Al Jamiah Street, Al Malaz District Riyadh 12629, Saudi Arabia.
Tel: +966 11 226 8850
Manufacture: Hetero Labs Limited Unit V, Hyderabad, India

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                October, 2023.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>